Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2026

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France, April 07, 2026--(BUSINESS WIRE)--Regulatory News:

Median Technologies (Paris:ALMDT):

(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260407652787/en/

Contacts

Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing & Financial Communications
+33 6 10 93 58 88
[email protected]

Investors – SEITOSEI ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
[email protected]

Press – MAARC
Bruno Arabian
+33 6 87 88 47 26
[email protected]